Updates of Radioiodine Treatment for Graves' Disease
International Journal of Thyroidology
;
: 85-90, 2019.
Article
in Korean
| WPRIM
| ID: wpr-785844
ABSTRACT
Radioiodine (RAI) has been used for the treatment of hyperthyroidism and is usually administered orally as sodium iodide (I-131) in solution or a capsule. However, this results in RAI being rapidly incorporated into the thyroid cells, and extensive local tissue damage occurring via beta emissions of I-131. The incidence rate of hypothyroidism is 5–50% at the first year after RAI therapy and is positively associated with the dosage of RAI. RAI has been used since 1960 in Korea; however, there have been few well-designed prospective trials, leaving many questions about indications, optimal dose, efficacy, and side-effects. This review summarizes the latest research pertaining to clinical questions about indications, optimal dose, efficacy, and side-effects.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Sodium Iodide
/
Thyroid Gland
/
Graves Disease
/
Incidence
/
Prospective Studies
/
Hyperthyroidism
/
Hypothyroidism
/
Korea
Type of study:
Incidence study
/
Observational study
/
Prognostic study
/
Risk factors
Country/Region as subject:
Asia
Language:
Korean
Journal:
International Journal of Thyroidology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS